Two trading sessions. Two upper circuits. A 35% rally in 48 hours. Cohance Lifesciences has been the most talked-about stock on Dalal Street this week, and the reason is a single board decision — the appointment of Umang Vohra, former Managing Director and Global CEO of Cipla, as Executive Chairman and Group CEO.
On Monday, the stock locked into a 20% upper circuit at Rs 432.10 on the NSE. On Tuesday, it extended gains by another 12.23% to Rs 484.95. Trading volumes on Monday alone jumped over threefold, with a combined 14.71 million shares changing hands on the NSE and BSE, and pending buy orders for around 650,000 shares at the upper circuit — a sign of overwhelming demand with almost no selling pressure.
The board decision that started it all
At its meeting on April 27, 2026, the board of Cohance Lifesciences noted the resignation of Vivek Sharma as Executive Chairman and Director with effect from April 30, 2026, and approved the appointment of Umang Vohra as Additional Director designated as Chairman with effect from May 1, 2026, and as Group CEO with effect from May 20, 2026. Sharma, who built the platform to its current form, will stay on as an advisor for nine months to support the transition.
Who is Umang Vohra
Vohra is among the most respected pharmaceutical executives India has produced. Over a career spanning more than three decades, he led Cipla as CEO and Managing Director, transforming it from a primarily domestic generics player into a diversified global pharmaceutical enterprise with a strengthened US pipeline, complex generics capabilities and a biosimilar strategy.
During his tenure, Cipla’s revenue expanded from roughly Rs 14,000 crore to over Rs 25,000 crore, with the US business scaling significantly and the company building capabilities in respiratory generics and complex injectables. His departure from Cipla in 2024 had been closely watched by India’s pharma investment community, with widespread expectation that he would surface at a platform commensurate with his experience.
Vohra himself has left little ambiguity about what drew him here. “I am very excited to be joining Cohance. I believe deeply in the long-term value creation potential of this platform. Cohance’s technology offerings, depth of its R&D talent, and the quality of the leadership team already in place provide a strong foundation. I am looking forward to this entrepreneurial stint,” he said.
Why a CDMO, and why now
The choice of Cohance as his next move is itself a signal. Cohance operates across three segments — pharma CRDMO, speciality chemicals and API++ — with a growing presence in high-value niche modalities such as antibody-drug conjugates, oligonucleotides and high-potent APIs. The company is one of the few CRDMO players in India to have successfully commercialised products in the ADC payload segment, which contributed about 17% to H1 FY26 revenue with a significantly higher gross margin profile.
Exports to regulated markets — the US and Europe — constituted approximately 87% of revenue in FY25, and the company holds top-three positions in eight out of ten of its top API molecules. The platform, in other words, already has the bones. What it needed was the leadership to accelerate the next chapter.
A CEO of Vohra’s calibre choosing a CDMO as his next platform sends a specific and bullish message about where the smartest operators in Indian pharma see the opportunity — not in finished dosage generics, but in the science-intensive, long-cycle, high-margin contract research and manufacturing business that global innovators increasingly want to outsource to trusted Indian partners.
The stock had hit a 52-week low of Rs 266.70 on March 9, 2026, before the Vohra announcement. Tuesday’s price of Rs 484.95 marks a 62% recovery from that low in under two months — most of it in the past 48 hours.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Please consult a qualified financial advisor before making investment decisions.Cohance Lifesciences stock up 35% in 2 days: Why Umang Vohra appointment triggered the rally